March 29, 2022 10:53 AM EDT

Antares Pharma wins FDA OK for oral testosterone treatment; Eye-focused biotech reports PhIII data for pupil dilation drug

Paul Schloesser

Associate Editor

Antares Pharma has nabbed another FDA approval, and the company’s second involving testosterone.
The New Jersey pharma announced the company’s approval …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Antares Pharma wins FDA OK for oral testosterone treatment; Eye-focused biotech reports PhIII data for pupil dilation drug

Paul Schloesser

Associate Editor

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Antares Phar­ma wins FDA OK for oral testos­terone treat­ment; Eye-fo­cused biotech re­ports PhI­II da­ta for pupil di­la­tion drug

Paul Schloesser

Associate Editor

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Antares Pharma wins FDA OK for oral testosterone treatment; Eye-focused biotech reports PhIII data for pupil dilation drug

CagriSema’s weight loss data disappointed. What does Novo do next?

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify